The global liquid biopsy market size was estimated to be USD 10.15 billion in 2023 and is expected to reach at USD 40.95 billion by 2034 with a CAGR of 13.52% during the forecast period 2024-2034. Increasing prevalence of oncology disorders, growing preference for minimally invasive diagnostics, rising geriatric population, surge in number of clinical trials for the development of novel liquid biopsy assays, increasing technological advancements, and rising investment by major market players for the development of new tests are some of the key factors boosting the market growth.
Rising investment by major market players for the development of new tests is predicted to boost the market growth during the forecast period. Precision oncology's fast developing liquid biopsy technique allows for least invasive molecular diagnosis and longitudinal monitoring for therapeutic objectives. In clinical practice, the quantification and detection of circulating DNA are now often utilized to treat advanced-stage lung cancer. Clinical studies now have new avenues to explore because of liquid biopsy technology, which is providing an additional source for cancer biomarkers. For instance, in July 2022, A MCED test that is both simple to use and effective was developed by Delfi Diagnostics, Inc. with $225 million in financing. The company is working on reducing the test's price to ensure it becomes more widely accessible to the general public.
By sample, blood sample was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the rising products approvals by regulatory bodies such as Guardant360 CDx & FoundationOne Liquid CDx that require blood samples for testing and increasing launch of new products. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of urine-based biopsy, growing launch of novel. For instance, in March 2022, miR Scientific, LLC unveiled their urine-sample-based liquid biopsy tests in the South East Asia and Singapore regions. Subsequently, the test was officially released for commercial use in the United States in July 2022.
By biomarker, circulating tumor cells (CTCs) biomarker was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to its usage as a key biomarker for the early identification of cancer in molecular tests, presence of novel products that detect CTC, and increasing regulatory approvals. Additionally, circulating tumor DNA (ctDNA) is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for cancer diagnosis, rising funding by government for the development of advanced test kits, and growing initiatives by market players. For instance, in May 2022, Cancer screening services using blood samples will now be offered across Europe, according to Guardant Health Inc. These services are now in operation at the liquid biopsy testing facility of the Vall d'Hebron Institute of Oncology (VHIO) located in Barcelona.
By product, instruments was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the growing launch of advanced instruments and the advancement of existing products. For instance, in June 2022, Tempus has expanded its range of comprehensive genomic profiling services by introducing xF+, a novel liquid biopsy panel comprised of 523 genes. This new non-invasive test specifically targets pathogenic mutations in cell-free DNA (cfDNA). Additionally, consumbale kits & reagents is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities by key market players for the development of advanced kits & reagents.
By technology, multi-gene-parallel analysis (NGS) was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the rising developments in NGS technology, increasing demand for sequencing of millions of different DNA molecules, and surge in introduction of various innovative products. For instance, in August 2022, Thermo Fisher Scientific Inc. has introduced the inaugural Next-Generation Sequencing (NGS) test capable of accommodating both DNA and RNA input. The Ion Torrent Oncomine Myeloid MRD Assays (ROU) offer a comprehensive and exceptionally sensitive assessment of measurable residual myeloid (MDR) presence in blood and bone marrow samples. Additionally, single gene analysis (PCR microarrays) is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of genetic disorders, rising focus on early diagnosis, and increasing research & development activities.
By application, cancer was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the growing prevalence of cancer, rising usage of liquid biopsy in screening its various forms, increasing research & development activities, and surge in launch of innovative systems. For instance, in November 2022, Thermo Fisher Scientific has launched digital PCR liquid-biopsy assays for its Applied Biosystems absolute Q dPCR system, alongside a custom design tool aimed at streamlining cancer research for academic and clinical research institutions. Additionally, reproductive health is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities in the field of liquid biopsy being taken into consideration for treating and maintaining reproductive health, surge in collaborations & partnerships within market players in the field of reproductive healthz.
By clinical applications, therapy selection was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the rising impact on the treatment regimens used to enhance patient outcomes, growing use of liquid biopsies can improve cancer therapies by enabling early intervention, enhancing treatment control, & moving the focus of decision-making from reactive actions to more proactive early interventions. Additionally, early cancer screening is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of cancer, surge in need to provide efficient methods for early detection of cancer, increasing research to develop & commercialize early screening tests by adopting the liquid biopsy technique, and rising launch of new products. For instance, in May 2022, The therascreen EGFR Plus RGQ PCR Kit, a novel in vitro diagnostic test for sensitive EGFR mutation analysis, was introduced by QIAGEN N.V.
By end-user, hospitals & laboratories was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the wide range of applications of liquid biopsy in hospitals for early screening & diagnosis of cancer patients, growing outsourcing activities for tests, and increasing launch of diagnostic platforms. For instance, in July 2022., Nanostics Inc. revealed the initiation of a validation study for their ClarityDX diagnostic platform, a clinical investigation of a noninvasive liquid biopsy test designed to detect bladder cancer. Additionally, academic & research centers is predicted to grow at fastest CAGR during the forecast period owing to the increasing research in the field of cancer detection, growing number of research & academic centers, surge in investment for research activities, and rising focus on development of liquid biopsy products in research centers.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of cancer, growing technological advancements, rising government initiatives, increasing FDA approvals for liquid biopsy tests, and surge partnership & collaborations within market players. For instance, in June 2022, F. Hoffmann-La Roche Ltd has collaborated with the Lung Cancer Research Foundation (LCRF) and the Lung Cancer Mutation Consortium (LCMC) to take part in the LCMC 4th screening trial. This trial aims to assess identifiable factors in the early stages of lung cancer with the goal of providing targeted therapy options for patients. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing healthcare infrastructure, rising usage of screening tests for cancer, growing government initiatives such as free screening for cervical, breast, & lung cancer, surge in collaborations between governments, research institutes, & companies, and increasing launch of novel products. For instance, in June 2023, Labcorp has introduced the Plasma Focus test, a liquid biopsy designed to identify biomarkers associated with cancers.
Rising investment by major market players for the development of new tests is predicted to boost the market growth during the forecast period. Precision oncology's fast developing liquid biopsy technique allows for least invasive molecular diagnosis and longitudinal monitoring for therapeutic objectives. In clinical practice, the quantification and detection of circulating DNA are now often utilized to treat advanced-stage lung cancer. Clinical studies now have new avenues to explore because of liquid biopsy technology, which is providing an additional source for cancer biomarkers. For instance, in July 2022, A MCED test that is both simple to use and effective was developed by Delfi Diagnostics, Inc. with $225 million in financing. The company is working on reducing the test's price to ensure it becomes more widely accessible to the general public.
By sample, blood sample was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the rising products approvals by regulatory bodies such as Guardant360 CDx & FoundationOne Liquid CDx that require blood samples for testing and increasing launch of new products. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of urine-based biopsy, growing launch of novel. For instance, in March 2022, miR Scientific, LLC unveiled their urine-sample-based liquid biopsy tests in the South East Asia and Singapore regions. Subsequently, the test was officially released for commercial use in the United States in July 2022.
By biomarker, circulating tumor cells (CTCs) biomarker was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to its usage as a key biomarker for the early identification of cancer in molecular tests, presence of novel products that detect CTC, and increasing regulatory approvals. Additionally, circulating tumor DNA (ctDNA) is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for cancer diagnosis, rising funding by government for the development of advanced test kits, and growing initiatives by market players. For instance, in May 2022, Cancer screening services using blood samples will now be offered across Europe, according to Guardant Health Inc. These services are now in operation at the liquid biopsy testing facility of the Vall d'Hebron Institute of Oncology (VHIO) located in Barcelona.
By product, instruments was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the growing launch of advanced instruments and the advancement of existing products. For instance, in June 2022, Tempus has expanded its range of comprehensive genomic profiling services by introducing xF+, a novel liquid biopsy panel comprised of 523 genes. This new non-invasive test specifically targets pathogenic mutations in cell-free DNA (cfDNA). Additionally, consumbale kits & reagents is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities by key market players for the development of advanced kits & reagents.
By technology, multi-gene-parallel analysis (NGS) was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the rising developments in NGS technology, increasing demand for sequencing of millions of different DNA molecules, and surge in introduction of various innovative products. For instance, in August 2022, Thermo Fisher Scientific Inc. has introduced the inaugural Next-Generation Sequencing (NGS) test capable of accommodating both DNA and RNA input. The Ion Torrent Oncomine Myeloid MRD Assays (ROU) offer a comprehensive and exceptionally sensitive assessment of measurable residual myeloid (MDR) presence in blood and bone marrow samples. Additionally, single gene analysis (PCR microarrays) is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of genetic disorders, rising focus on early diagnosis, and increasing research & development activities.
By application, cancer was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the growing prevalence of cancer, rising usage of liquid biopsy in screening its various forms, increasing research & development activities, and surge in launch of innovative systems. For instance, in November 2022, Thermo Fisher Scientific has launched digital PCR liquid-biopsy assays for its Applied Biosystems absolute Q dPCR system, alongside a custom design tool aimed at streamlining cancer research for academic and clinical research institutions. Additionally, reproductive health is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities in the field of liquid biopsy being taken into consideration for treating and maintaining reproductive health, surge in collaborations & partnerships within market players in the field of reproductive healthz.
By clinical applications, therapy selection was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the rising impact on the treatment regimens used to enhance patient outcomes, growing use of liquid biopsies can improve cancer therapies by enabling early intervention, enhancing treatment control, & moving the focus of decision-making from reactive actions to more proactive early interventions. Additionally, early cancer screening is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of cancer, surge in need to provide efficient methods for early detection of cancer, increasing research to develop & commercialize early screening tests by adopting the liquid biopsy technique, and rising launch of new products. For instance, in May 2022, The therascreen EGFR Plus RGQ PCR Kit, a novel in vitro diagnostic test for sensitive EGFR mutation analysis, was introduced by QIAGEN N.V.
By end-user, hospitals & laboratories was the highest revenue-grossing segment in the global liquid biopsy market in 2023 owing to the wide range of applications of liquid biopsy in hospitals for early screening & diagnosis of cancer patients, growing outsourcing activities for tests, and increasing launch of diagnostic platforms. For instance, in July 2022., Nanostics Inc. revealed the initiation of a validation study for their ClarityDX diagnostic platform, a clinical investigation of a noninvasive liquid biopsy test designed to detect bladder cancer. Additionally, academic & research centers is predicted to grow at fastest CAGR during the forecast period owing to the increasing research in the field of cancer detection, growing number of research & academic centers, surge in investment for research activities, and rising focus on development of liquid biopsy products in research centers.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of cancer, growing technological advancements, rising government initiatives, increasing FDA approvals for liquid biopsy tests, and surge partnership & collaborations within market players. For instance, in June 2022, F. Hoffmann-La Roche Ltd has collaborated with the Lung Cancer Research Foundation (LCRF) and the Lung Cancer Mutation Consortium (LCMC) to take part in the LCMC 4th screening trial. This trial aims to assess identifiable factors in the early stages of lung cancer with the goal of providing targeted therapy options for patients. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing healthcare infrastructure, rising usage of screening tests for cancer, growing government initiatives such as free screening for cervical, breast, & lung cancer, surge in collaborations between governments, research institutes, & companies, and increasing launch of novel products. For instance, in June 2023, Labcorp has introduced the Plasma Focus test, a liquid biopsy designed to identify biomarkers associated with cancers.
Segmentation: Liquid Biopsy Market Report 2022 - 2033
Liquid Biopsy Market Analysis & Forecast by Sample 2022 - 2033 (Revenue USD Bn)
- Blood Sample
- Others
Liquid Biopsy Market Analysis & Forecast by Biomarker 2022 - 2033 (Revenue USD Bn)
- Circulating Tumor DNA (ctDNA)
- Extracellular Vesicles (EVs)
- Circulating Tumor Cells (CTCs)
- Others
Liquid Biopsy Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
- Consumables Kits & Reagents
- Instruments
- Software and Services
Liquid Biopsy Market Analysis & Forecast by Technology 2022 - 2033 (Revenue USD Bn)
- Single Gene Analysis (PCR Microarrays)
- Multi-gene-parallel Analysis (NGS))
Liquid Biopsy Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Reproductive Health
- Cancer
- Breast Cancer
- Leukemia
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Others
Liquid Biopsy Market Analysis & Forecast by Clinical Applications 2022 - 2033 (Revenue USD Bn)
- Early Cancer Screening
- Therapy Selection
- Recurrence Monitoring
- Treatment Monitoring
- Others
Liquid Biopsy Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Academic & Research Centers
- Hospitals & Laboratories
- Specialty Clinics
- Others
Liquid Biopsy Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Liquid Biopsy Market: Sample Estimates & Trend Analysis
8. Liquid Biopsy Market: Biomarker Estimates & Trend Analysis
9. Liquid Biopsy Market: Product Estimates & Trend Analysis
10. Liquid Biopsy Market: Technology Estimates & Trend Analysis
11. Liquid Biopsy Market: Application Estimates & Trend Analysis
12. Liquid Biopsy Market: Clinical Application Estimates & Trend Analysis
13. Liquid Biopsy Market: End-user Estimates & Trend Analysis
14. Regional Market Analysis
15. North America Liquid Biopsy Market
16. Europe Global Liquid Biopsy Market
17. Asia Pacific Global Liquid Biopsy Market
18. Latin America Global Liquid Biopsy Market
19. MEA Global Liquid Biopsy Market
20. Competitor Analysis
21. Company Profiles
Companies Mentioned
- Biocept Inc.
- ANGLE plc
- Oncimmune
- Guardant Health Inc.
- Thermo Fisher Scientific Inc.
- Myriad Genetics Inc.
- QIAGEN
- Freenome Holdings Inc.
- F. Hoffmann-La Roche Ltd.
- Epigenomics AG
- Lucence Health Inc.
- Illumina Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 10.15 Billion |
| Forecasted Market Value ( USD | $ 40.95 Billion |
| Compound Annual Growth Rate | 13.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
